, Huapyong Kang2
, Jae Hee Cho3
1Department of Gastroenterology, Aichi Medical University, Aichi, Japan
2Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Tadahisa Inoue received honoraria from Boston Scientific Japan and Japan Lifeline Co., Ltd., Ltd, outside the submitted work. The other authors have no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: TI; Data curation: TI; Formal analysis: TI; Investigation: TI; Methodology: all authors; Supervision: all authors; Visualization: TI; Writing–original draft: TI; Writing–review & editing: HK, JHC.
| Study | Year | No. of patients | Etiology | Location | EB-RFAcatheter | EB-RFAsetting | Stent type | No. of EB-RFA applications | Stent patency period(median/mean) | Survival period(median/mean) | Adverse event rate | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EB-RFA+stent | Stent | EB-RFA+stent | Stent | p-value | EB-RFA+stent | Stent | p-value | EB-RFA+stent (%) | Stent (%) | p-value | ||||||||
| Yang et al.15 | 2018 | 32 | 33 | Cholangiocarcinoma | Distal, hilar | Habib | 7–10 W 90 s | PS | Every 3 moa) | 6.8 mob) | 3.4 mo | 0.02 | 13.2 mo | 8.3 mo | <0.001 | 6.3 | 9.1 | 0.67 |
| Kang et al.16,c) | 2021 | 24 | 24 | Cholangiocarcinoma, Pancreatic cancer, Other | Distal, hilar | ELRA | 7 W/10W 120 s80 ℃ | UMS | 1 | 132 day | 116 day | 0.440 | 244 d | 180 d | 0.281 | 4.2 | 12.5 | 0.609 |
| Gao et al.17 | 2021 | 87 | 87 | Cholangiocarcinomad) | Distal, hilar | Habib | 7–10 W90 s | PS | 2 | 3.7 mo | 4.1 mo | 0.674 | 14.3 mo | 9.2 mo | <0.001 | 27.6(early event) | 19.5(early event) | 0.211 |
| Kang et al.18 | 2022 | 15 | 15 | Cholangiocarcinoma, Gallbladder cancer | Hilar | ELRA | 7 W60–120 s80 ℃ | UMS | 1-2 | 178 day | 122 day | 0.154 | 230 day | 144 day | 0.643 | NA | NA | NS |
| Albers et al.19 | 2022 | 42 | 44 | Cholangiocarcinoma, Pancreatic cancer, Other | Distal, hilar | Habib | 10 W90 s | UMS | 1 | NAe) | NAe) | NAe) | NAe) | NAe) | NAe) | 10.5 | 2.3 | 0.18 |
| Jarosova et al.20 | 2023 | 44 | 41 | Cholangiocarcinoma | Distal, hilar | Habib | 10 W120 s | UMS/CMS | 1 | NAf) | NAf) | NAf) | 10.5 mo | 10.6 mo | 0.58 | 13.6 | 9.8 | NS |
| 37 | 39 | Pancreatic cancer | Distal | Habib | 10 W120 s | CMS | 1 | NAf) | NAf) | NAf) | 6.4 mo | 7.7 mo | 0.73 | 2.7 | 7.7 | NS | ||
EB-RFA, endobiliary radiofrequency ablation; PS, plastic stent; UMS, uncovered metal stent; NA, not applicable; NS, not significant; CMS, covered metal stent.
a)EB-RFA was repeated if the bile duct wall thickness was >6 mm on intraductal ultrasonography performed every 3 months.
b)Stent replacement was performed every 3 months regardless of occlusion.
c)Cases involving percutaneous approaches were also included.
d)Cases of ampullary cancers were also included.
e)Stent patency and overall survival rates at 3 and 6 months did not differ significantly between the groups.
f)Stent patency at 3, 6, 9, and 12 months did not differ significantly between the groups.
| Study | Year | Study design | Treatment | No. of patients | Location | Metastatic (%) | EB-RFA catheter | Stent type | No. of EB-RFA applications | Stent patency period (median, mo) | Progression-free survival (median, mo) | Overall survival (median, mo) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yang et al.23 | 2020 | RCT | S-1 chemotherapy+EB-RFA | 37 | Distal, hilar | 0 | Habib | PS | 3.3 (mean) | 6.6 | p=0.014 | 12 | p<0.001 | 16.0 | p<0.001 |
| ID-RFA | 38 | Distal, hilar | 0 | Habib | PS | 2.4 (mean) | 5.6 | 7 | 11.0 | ||||||
| Gonzalez-Carmona et al.24 | 2022 | Retrospective | GEM-based chemotherapy+EB-RFA | 40 | Distal, hilar | 37.5 | Habib | PS | 1–21 | NA | NA | 12.9 | p=0.045 | 17.3 | p=0.004 |
| GEM-based chemotherapy | 26 | Distal, hilar | 50.0 | Habib | PS | - | NA | 5.7 | 8.6 | ||||||
| Inoue et al.25 | 2022 | Retrospective | GEM with cisplatin+EB-RFA | 25 | Distal, hilar | 48 | Habib | UMS | 1.84 (mean) | 10.7 | p=0.048 | 8.6 | p=0.014 | 17.1 | p=0.017 |
| GEM with cisplatin | 25 | Distal, hilar | 60 | Habib | UMS | - | 5.2 | 5.8 | 11.3 | ||||||
| Study | Year | Study design | No. of patients | Etiology | Stricture location | EB-RFA catheter | RFA settings | Stent patency period after reintervention (median/mean) | Adverse event rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EB-RFA | Control | EB-RFA (day) | Control (day) | p-value | EB-RFA (%) | Control | p-value | |||||||
| Kadayifci et al.31 | 2016 | Retrospective | 25 | 25 (PS) | Cholangiocarcinoma, pancreatic cancer, other | - | Habib | 10 W 90 s | 119.5 | 65.3 | 0.03 | 0 (significant event) | 0 (significant event) | NS |
| Park et al.39 | 2023 | Retrospective | 9 (with UMS)a) | 9 (UMS alone)a) | Cholangiocarcinoma, pancreatic cancer | Distal | ELRA | 80 ℃ 120 s | 117 | 82.5 | 0.029 | 0 (significant event) | 0 (significant event) | NS |
| Inoue et al.35 | 2025 | Retrospective | 40a) | 40 (PS)a) | Cholangiocarcinoma, other | Hilar | Habib | 10 W 90 s | 163 | 89 | 0.015 | 7.5 | 5 | NS |
| Study | Year | No. of patients | Etiology | Location | EB-RFAcatheter | EB-RFAsetting | Stent type | No. of EB-RFA applications | Stent patency period(median/mean) | Survival period(median/mean) | Adverse event rate | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EB-RFA+stent | Stent | EB-RFA+stent | Stent | p-value | EB-RFA+stent | Stent | p-value | EB-RFA+stent (%) | Stent (%) | p-value | ||||||||
| Yang et al.15 | 2018 | 32 | 33 | Cholangiocarcinoma | Distal, hilar | Habib | 7–10 W 90 s | PS | Every 3 mo |
6.8 mo |
3.4 mo | 0.02 | 13.2 mo | 8.3 mo | <0.001 | 6.3 | 9.1 | 0.67 |
| Kang et al.16, |
2021 | 24 | 24 | Cholangiocarcinoma, Pancreatic cancer, Other | Distal, hilar | ELRA | 7 W/10W 120 s80 ℃ | UMS | 1 | 132 day | 116 day | 0.440 | 244 d | 180 d | 0.281 | 4.2 | 12.5 | 0.609 |
| Gao et al.17 | 2021 | 87 | 87 | Cholangiocarcinoma |
Distal, hilar | Habib | 7–10 W90 s | PS | 2 | 3.7 mo | 4.1 mo | 0.674 | 14.3 mo | 9.2 mo | <0.001 | 27.6(early event) | 19.5(early event) | 0.211 |
| Kang et al.18 | 2022 | 15 | 15 | Cholangiocarcinoma, Gallbladder cancer | Hilar | ELRA | 7 W60–120 s80 ℃ | UMS | 1-2 | 178 day | 122 day | 0.154 | 230 day | 144 day | 0.643 | NA | NA | NS |
| Albers et al.19 | 2022 | 42 | 44 | Cholangiocarcinoma, Pancreatic cancer, Other | Distal, hilar | Habib | 10 W90 s | UMS | 1 | NA |
NA |
NA |
NA |
NA |
NA |
10.5 | 2.3 | 0.18 |
| Jarosova et al.20 | 2023 | 44 | 41 | Cholangiocarcinoma | Distal, hilar | Habib | 10 W120 s | UMS/CMS | 1 | NA |
NA |
NA |
10.5 mo | 10.6 mo | 0.58 | 13.6 | 9.8 | NS |
| 37 | 39 | Pancreatic cancer | Distal | Habib | 10 W120 s | CMS | 1 | NA |
NA |
NA |
6.4 mo | 7.7 mo | 0.73 | 2.7 | 7.7 | NS | ||
| Study | Year | Study design | Treatment | No. of patients | Location | Metastatic (%) | EB-RFA catheter | Stent type | No. of EB-RFA applications | Stent patency period (median, mo) | Progression-free survival (median, mo) | Overall survival (median, mo) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yang et al.23 | 2020 | RCT | S-1 chemotherapy+EB-RFA | 37 | Distal, hilar | 0 | Habib | PS | 3.3 (mean) | 6.6 | p=0.014 | 12 | p<0.001 | 16.0 | p<0.001 |
| ID-RFA | 38 | Distal, hilar | 0 | Habib | PS | 2.4 (mean) | 5.6 | 7 | 11.0 | ||||||
| Gonzalez-Carmona et al.24 | 2022 | Retrospective | GEM-based chemotherapy+EB-RFA | 40 | Distal, hilar | 37.5 | Habib | PS | 1–21 | NA | NA | 12.9 | p=0.045 | 17.3 | p=0.004 |
| GEM-based chemotherapy | 26 | Distal, hilar | 50.0 | Habib | PS | - | NA | 5.7 | 8.6 | ||||||
| Inoue et al.25 | 2022 | Retrospective | GEM with cisplatin+EB-RFA | 25 | Distal, hilar | 48 | Habib | UMS | 1.84 (mean) | 10.7 | p=0.048 | 8.6 | p=0.014 | 17.1 | p=0.017 |
| GEM with cisplatin | 25 | Distal, hilar | 60 | Habib | UMS | - | 5.2 | 5.8 | 11.3 | ||||||
| Study | Year | Study design | No. of patients | Etiology | Stricture location | EB-RFA catheter | RFA settings | Stent patency period after reintervention (median/mean) | Adverse event rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EB-RFA | Control | EB-RFA (day) | Control (day) | p-value | EB-RFA (%) | Control | p-value | |||||||
| Kadayifci et al.31 | 2016 | Retrospective | 25 | 25 (PS) | Cholangiocarcinoma, pancreatic cancer, other | - | Habib | 10 W 90 s | 119.5 | 65.3 | 0.03 | 0 (significant event) | 0 (significant event) | NS |
| Park et al.39 | 2023 | Retrospective | 9 (with UMS) |
9 (UMS alone) |
Cholangiocarcinoma, pancreatic cancer | Distal | ELRA | 80 ℃ 120 s | 117 | 82.5 | 0.029 | 0 (significant event) | 0 (significant event) | NS |
| Inoue et al.35 | 2025 | Retrospective | 40 |
40 (PS) |
Cholangiocarcinoma, other | Hilar | Habib | 10 W 90 s | 163 | 89 | 0.015 | 7.5 | 5 | NS |
EB-RFA, endobiliary radiofrequency ablation; PS, plastic stent; UMS, uncovered metal stent; NA, not applicable; NS, not significant; CMS, covered metal stent. EB-RFA was repeated if the bile duct wall thickness was >6 mm on intraductal ultrasonography performed every 3 months. Stent replacement was performed every 3 months regardless of occlusion. Cases involving percutaneous approaches were also included. Cases of ampullary cancers were also included. Stent patency and overall survival rates at 3 and 6 months did not differ significantly between the groups. Stent patency at 3, 6, 9, and 12 months did not differ significantly between the groups.
EB-RFA, endobiliary radiofrequency ablation; RCT, randomized controlled trial; PS, plastic stent; ID-RFA, intraductal radiofrequency ablation; NA, not applicable; UMS, uncovered metal stent; GEM, gemcitabine; -, not applicable.
EB-RFA, endobiliary radiofrequency ablation; NS, not significant; PS, plastic stent; UMS, uncovered metal stent; -, not applicable. These are based on the propensity score–matched cohort.
